Hydrochloric Acid

Hydrochloric Acid

SCHEMBL4489744

Cl.Cl.NNC(=O)NN

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6335251 1.00
Hydrazine SCHEMBL28088113 0.96
SCHEMBL64716 0.95
SCHEMBL20178517 0.95 NFKB1 (0.54)
SCHEMBL10623380 0.95 NFKB1 (0.54)
SCHEMBL8014825 0.91
Potassium SCHEMBL18585217 0.91
SCHEMBL8017494 0.91
SCHEMBL1537923 0.91
Water SCHEMBL7464138 0.91

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3966279-B1 CURABLE FLUOROELASTOMER COMPOSITIONS DUPONT SPECIALTY PRODUCTS USA LLC (US) 2024-08-21 EP claimed
EP-2691455-B1 CURABLE FLUOROELASTOMER COMPOSITION DUPONT SPECIALTY PRODUCTS USA LLC (US) 2024-03-13 EP claimed
US-20220306782-A1 CURABLE FLUOROELASTOMER COMPOSITIONS DUPONT SPECIALTY PRODUCTS USA, LLC 2022-09-29 US claimed
EP-3966279-A1 CURABLE FLUOROELASTOMER COMPOSITIONS DUPONT POLYMERS, INC. (US) 2022-03-16 EP claimed
CN-114127160-A Curable fluoroelastomer compositions 杜邦聚合物公司 2022-03-01 CN claimed
US-11078354-B2 Fluoroelastomer compounds E.I. DEUPONT DE NEMOURS AND COMPANY (US) 2021-08-03 US claimed
WO-2020227485-A1 CURABLE FLUOROELASTOMER COMPOSITIONS DUPONT POLYMERS, INC. (US) 2020-11-12 WO claimed
US-20200283611-A1 FLUOROELASTOMER COMPOUNDS DUPONT SPECIALTY PRODUCTS USA, LLC 2020-09-10 US claimed
EP-3408320-A1 FLUOROELASTOMER COMPOUNDS E. I. du Pont de Nemours and Company (US) 2018-12-05 EP claimed
WO-2017132706-A1 FLUOROELASTOMER COMPOUNDS E I DU PONT DE NEMOURS AND COMPANY (US) 2017-08-03 WO claimed
US-12173099-B2 Curable fluoroelastomer compositions DUPONT POLYMERS, INC. (US) 2024-12-24 US disclosed
EP-3966279-B1 CURABLE FLUOROELASTOMER COMPOSITIONS DUPONT SPECIALTY PRODUCTS USA LLC (US) 2024-08-21 EP disclosed
EP-2691455-B1 CURABLE FLUOROELASTOMER COMPOSITION DUPONT SPECIALTY PRODUCTS USA LLC (US) 2024-03-13 EP disclosed
CN-114127160-B Curable fluoroelastomer compositions 杜邦聚合物公司 2023-08-15 CN disclosed
US-20220306782-A1 CURABLE FLUOROELASTOMER COMPOSITIONS DUPONT SPECIALTY PRODUCTS USA, LLC 2022-09-29 US disclosed
WO-2020227485-A1 CURABLE FLUOROELASTOMER COMPOSITIONS DUPONT POLYMERS, INC. (US) 2020-11-12 WO disclosed
CN-110467581-A A kind of anhydrous nonmetallic pentazole ion salt and preparation method thereof UNIV NANJING SCI & TECH 2019-11-19 CN disclosed
US-7528148-B2 Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2009-05-05 US disclosed
US-20060252790-A1 Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2006-11-09 US disclosed
CN-1500080-A Fused heterocyclic compounds ����ҩƷ��ҵ��ʽ���� 2004-05-26 CN disclosed